Esperovax Announces U.S. Patent Allowance for In Vivo Therapeutic Protein Expression Platform

Patent ExpiryapprovedPositive

AI Analysis

Summary

Esperovax announced U.S. Patent allowance for its yeast-based therapeutic protein expression platform technology. The patent provides intellectual property protection for the company's in vivo expression approach.

Outcome Details

U.S. Patent Application No. 18/038,673 issued Notice of Allowance for yeast-based expression of therapeutic proteins in vivo

Importance:4/10

Sentiment:

0.60

patentintellectual propertyplatform technologytherapeutic proteinsin vivo expression

Related Companies

$UTHR

Read the original article

Published by PR Newswire Biotech on September 11, 2026 2:44 PM

Read Original